
US-based Immunitas advances immuno-oncology therapeutics through an integrated genomics platform.
Immunitas Therapeutics, founded in Waltham, United States, is dedicated to advancing immuno-oncology therapeutics. The company's core mission is to discover and develop novel, differentiated treatments for cancer patients. Utilizing a highly integrated single-cell genomics platform, Immunitas rapidly identifies and validates targets while simultaneously discovering antibodies. Their market focus is on precision immunotherapy, leveraging deep expertise in single-cell genomics and machine learning to understand immune cell populations.
Notable figures associated with Immunitas include leading experts in genomics and oncology. The company has attracted significant investment from prominent venture capital firms in the biotech sector. Key achievements include the successful advancement of multiple therapeutic programs to clinical stages. Immunitas' impact lies in its innovative approach to cancer treatment, promising more effective and personalized therapies for patients.

Immune-Onc Therapeutics
immuneonc.com

Immunai

ImmunoGenesis
immunogenesis.com

INmune Bio
inmunebio.com

ImmunoMet Therapeutics
immunomet.com

ImmunoMind

ImmuneID

Immunome

Imvaq Therapeutics

ImmuneXcite

Inimmune
inimmune.com

ImmuneSensor Therapeutics
immunesensor.com

GO Therapeutics
gotherapeutics.com

ImmunityBio
immunitybio.com

Immpact Bio
immpact-bio.com
Companies similar to Immunitas Therapeutics include Immune-Onc Therapeutics, Immunai, ImmunoGenesis and INmune Bio.
Immunitas Therapeutics was founded in 2019.
Immunitas Therapeutics' headquarters is located in Waltham, MA, US.
Immunitas Therapeutics' most recent funding round was for $58M (USD) in August 2021.
As of Aug 18, 2021, Immunitas Therapeutics has raised a total of $97M (USD).
Immunitas Therapeutics has 33 employees as of Feb 5, 2024.